Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells

SIMPLE SUMMARY: Chimeric antigen receptor (CAR) T cell treatment is a promising adoptive cell therapy that utilises CAR-expressing primary T cells to target specific tumour antigens. Since its first approval in 2017, the FDA has approved six CAR T cell therapies for blood cancer treatment. Despite t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Grace Min Yi, Poudel, Aarati, Ali Hosseini Rad, Seyed Mohammad, McLellan, Alexander Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564159/
https://www.ncbi.nlm.nih.gov/pubmed/36230780
http://dx.doi.org/10.3390/cancers14194854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564159/
https://www.ncbi.nlm.nih.gov/pubmed/36230780
http://dx.doi.org/10.3390/cancers14194854

Ejemplares similares